These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2494 related articles for article (PubMed ID: 29863955)
1. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. Socinski MA; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kelsch C; Lee A; Coleman S; Deng Y; Shen Y; Kowanetz M; Lopez-Chavez A; Sandler A; Reck M; N Engl J Med; 2018 Jun; 378(24):2288-2301. PubMed ID: 29863955 [TBL] [Abstract][Full Text] [Related]
2. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA; Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878 [TBL] [Abstract][Full Text] [Related]
3. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. Socinski MA; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kong S; Lee A; Coleman S; Zou W; McCleland M; Shankar G; Reck M J Thorac Oncol; 2021 Nov; 16(11):1909-1924. PubMed ID: 34311108 [TBL] [Abstract][Full Text] [Related]
4. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901 [TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375 [TBL] [Abstract][Full Text] [Related]
6. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. Nogami N; Barlesi F; Socinski MA; Reck M; Thomas CA; Cappuzzo F; Mok TSK; Finley G; Aerts JG; Orlandi F; Moro-Sibilot D; Jotte RM; Stroyakovskiy D; Villaruz LC; Rodríguez-Abreu D; Wan-Teck Lim D; Merritt D; Coleman S; Lee A; Shankar G; Yu W; Bara I; Nishio M J Thorac Oncol; 2022 Feb; 17(2):309-323. PubMed ID: 34626838 [TBL] [Abstract][Full Text] [Related]
7. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. Reck M; Wehler T; Orlandi F; Nogami N; Barone C; Moro-Sibilot D; Shtivelband M; González Larriba JL; Rothenstein J; Früh M; Yu W; Deng Y; Coleman S; Shankar G; Patel H; Kelsch C; Lee A; Piault E; Socinski MA J Clin Oncol; 2020 Aug; 38(22):2530-2542. PubMed ID: 32459597 [TBL] [Abstract][Full Text] [Related]
8. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. Herbst RS; Giaccone G; de Marinis F; Reinmuth N; Vergnenegre A; Barrios CH; Morise M; Felip E; Andric Z; Geater S; Özgüroğlu M; Zou W; Sandler A; Enquist I; Komatsubara K; Deng Y; Kuriki H; Wen X; McCleland M; Mocci S; Jassem J; Spigel DR N Engl J Med; 2020 Oct; 383(14):1328-1339. PubMed ID: 32997907 [TBL] [Abstract][Full Text] [Related]
9. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With Park S; Kim TM; Han JY; Lee GW; Shim BY; Lee YG; Kim SW; Kim IH; Lee S; Kim YJ; Park JH; Park SG; Lee KH; Kang EJ; Kim JW; Shin SH; Ock CY; Nam BH; Lee J; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ J Clin Oncol; 2024 Apr; 42(11):1241-1251. PubMed ID: 37861993 [TBL] [Abstract][Full Text] [Related]
10. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis. Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562 [TBL] [Abstract][Full Text] [Related]
12. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. Shiraishi Y; Kishimoto J; Sugawara S; Mizutani H; Daga H; Azuma K; Matsumoto H; Hataji O; Nishino K; Mori M; Shukuya T; Saito H; Tachihara M; Hayashi H; Tsuya A; Wakuda K; Yanagitani N; Sakamoto T; Miura S; Hata A; Okada M; Kozuki T; Sato Y; Harada T; Takayama K; Yamamoto N; Nakagawa K; Okamoto I JAMA Oncol; 2024 Mar; 10(3):315-324. PubMed ID: 38127362 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Hopkins AM; Kichenadasse G; McKinnon RA; Abuhelwa AY; Logan JM; Badaoui S; Karapetis CS; Rowland A; Sorich MJ Br J Cancer; 2022 Jan; 126(1):42-47. PubMed ID: 34711947 [TBL] [Abstract][Full Text] [Related]
14. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957 [TBL] [Abstract][Full Text] [Related]
15. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877 [TBL] [Abstract][Full Text] [Related]
16. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial. Provencio M; Ortega AL; Coves-Sarto J; Calvo V; Marsé-Fabregat R; Dómine M; Guirado M; Carcereny E; Fernández N; Álvarez R; Blanco R; León-Mateos L; Sánchez-Torres JM; Sullivan IG; Cobo M; Sánchez-Hernández A; Massuti B; Sierra-Rodero B; Mártinez-Toledo C; Serna-Blasco R; Romero A; Cruz-Bermúdez A JAMA Oncol; 2023 Mar; 9(3):344-353. PubMed ID: 36520426 [TBL] [Abstract][Full Text] [Related]
17. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. Horn L; Mansfield AS; Szczęsna A; Havel L; Krzakowski M; Hochmair MJ; Huemer F; Losonczy G; Johnson ML; Nishio M; Reck M; Mok T; Lam S; Shames DS; Liu J; Ding B; Lopez-Chavez A; Kabbinavar F; Lin W; Sandler A; Liu SV; N Engl J Med; 2018 Dec; 379(23):2220-2229. PubMed ID: 30280641 [TBL] [Abstract][Full Text] [Related]
18. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA; N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906 [TBL] [Abstract][Full Text] [Related]
19. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study). Watanabe S; Furuya N; Nakamura A; Shiihara J; Nakachi I; Tanaka H; Nakao M; Minato K; Seike M; Sasaki S; Kisohara A; Takeuchi S; Honda R; Takamura K; Kagamu H; Yoshimura K; Kobayashi K; Kikuchi T Eur J Cancer; 2024 Jan; 197():113469. PubMed ID: 38061214 [TBL] [Abstract][Full Text] [Related]
20. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA; Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]